SEARCH

SEARCH BY CITATION

References

  • 1
    Mangano DT, Browner WS, Hollenberg M, et al. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The study of perioperative ischemia research group. N Engl J Med. 1990;323:17811788.
  • 2
    Shah KB, Kleinman BS, Rao TL, et al. Angina and other risk factors in patients with cardiac diseases undergoing noncardiac operations. Anesth Analg. 1990;70:240247.
  • 3
    Badner NH, Knill RL, Brown JE, et al. Myocardial infarction after noncardiac surgery. Anesthesiology. 1998;88:572578.
  • 4
    Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med. 1977;297:845850.
  • 5
    Zaman AG, Helft G, Worthley SG, et al. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis. 2000;149:251266.
  • 6
    Dunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (decrease-iv). Ann Surg. 2009;249:921926.
  • 7
    Bangalore S, Wetterslev J, Pranesh S, et al. Perioperative beta blockers in patients having non- cardiac surgery: a meta-analysis. Lancet. 2008;372:19621976.
  • 8
    Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation. 2001;103:926933.
  • 9
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4 s). Lancet. 1994;344:13831389.
  • 10
    Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (lipid) study group. N Engl J Med. 1998;339:13491357.
  • 11
    Pan W, Pintar T, Anton J, et al. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation. 2004;110:II45II49.
  • 12
    Thielmann M, Neuhauser M, Marr A, et al. Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2007;134:11431149.
  • 13
    Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation. 2003;107:18481851.
  • 14
    O'Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the statins for risk reduction in surgery (starrs) study. J Am Coll Cardiol. 2005;45:336342.
  • 15
    Ward RP, Leeper NJ, Kirkpatrick JN, et al. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol. 2005;104:264268.
  • 16
    Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg. 2008;106:685712.
  • 17
    Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50:21732195.
  • 18
    Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 2001;38:21142130.
  • 19
    Mathew JP, Parks R, Savino JS, et al. Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. Multicenter study of Perioperative Ischemia Research Group. JAMA. 1996;276:300306.
  • 20
    Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley; 2000.
  • 21
    Luo Z, Gardiner JC, Bradley CJ. Applying propensity score methods in medical research: pitfalls and prospects. Med Care Res Rev. 2010;67:528554.
  • 22
    Wilhelmsen L, Pyorala K, Wedel H, et al. Risk factors for a major coronary event after myocardial infarction in the scandinavian simvastatin survival study (4 s). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J. 2001;22:11191127.
  • 23
    Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol. 2013;28:718.
  • 24
    Chopra V, Wesorick DH, Sussman JB, et al. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta- analysis. Arch Surg. 2012;147:181189.
  • 25
    Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:17691781.
  • 26
    Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:14401445.
  • 27
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359:21952207.
  • 28
    Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:2028.
  • 29
    McCarey DW, McInnes IB, Madhok R, et al. Trial of atorvastatin in rheumatoid arthritis (tara): double-blind, randomised placebo-controlled trial. Lancet. 2004;363:20152021.
  • 30
    Undas A, Brummel KE, Musial J, et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103:22482253.
  • 31
    Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol. 1999;33:12941304.
  • 32
    Mayer J, Eller T, Brauer P, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 1992;64:196201.
  • 33
    Abela GS, Vedre A, Janoudi A, et al. Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am J Cardiol. 2011;107:17101717.
  • 34
    Ellis SG, Hertzer NR, Young JR, et al. Angiographic correlates of cardiac death and myocardial infarction complicating major nonthoracic vascular surgery. Am J Cardiol. 1996;77:11261128.
  • 35
    Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002;106:804808.
  • 36
    Abela GS, Aziz K, Vedre A, et al. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am J Cardiol. 2009;103:959968.
  • 37
    Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005;46:14251433.
  • 38
    Le Manach Y, Coriat P, Collard CD, et al. Statin therapy within the perioperative period. Anesthesiology. 2008;108:11411146.
  • 39
    Hindler K, Shaw AD, Samuels J, et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology. 2006;105:12601272; quiz 1289–1290.
  • 40
    Xu SZ, Zhong W, Watson NM, et al. Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2. J Thromb Haemost. 2008;6:692700.